At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
asfotase alfabiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label Study of the Safety, Tolerability and Pharmacology of Asfotase Alfa in up to 10 Severely Affected Patients With for the Treatment of Severely Affected Patients With Infantile Hypophosphatasia (HPP)
In Brief
A Phase 2 clinical trial evaluating asfotase alfa for Hypophosphatasia (HPP). Completed, enrolled 11 participants across 10 sites in 4 countries.
Detailed Summary
This clinical trial studies the safety and efficacy of asfotase alfa in infants and young children with infantile onset HPP.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypophosphatasia (HPP)
CountriesCanada, United Arab Emirates, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2008
Enrollment StartSep 2008
Primary CompletionMay 2010
TodayJul 2026
First PostedAug 29, 2008
Enrollment StartSep 1, 2008
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 17.8 years ago
Interventions
asfotase alfabiological